logo BDSP

Base documentaire

  1. Cost of complete remission induction in acute myeloblastic leukemia : evaluation of the cost-effectiveness of a new drug.

    Article - En anglais

    The use of new drugs in the treatment of AML could dramatically increase the cost of induction chemotherapy.

    To evaluate the cost-effectiveness of such new drugs, the overall cost to achieve complete remission (CR) with treatments including these drugs has to be compared to the cost of the daunorubicin-cytosine arabinoside (DNR-AraC) association, considered as the reference treatment.

    A retrospective analysis of charts from 15 patients treated with DNR-AraC was used to identify 228 items of cost, including general cost, diagnostic, supportive care, and chemotherapy.

    Mots-clés Pascal : Leucémie myéloblastique, Cytarabine, Anthraquinone, Anticancéreux, Pyrimidine nucléoside, Hémopathie maligne, Aigu, Anthracyclines, Daunorubicine, Mitoxantrone, Analyse coût efficacité, Chimiothérapie, Traitement induction, Rémission, Economie santé, Homme

    Mots-clés Pascal anglais : Acute myelocytic leukemia, Anthraquinone, Antineoplastic agent, Pyrimidine nucleoside, Malignant hemopathy, Acute, Anthracyclins, Cost efficiency analysis, Chemotherapy, Induction treatment, Remission, Health economy, Human

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 92-0623266

    Code Inist : 002B02R02. Création : 199406.